Investor Presentation — MagSense^® Imaging

Oct 28, 2019
Posted in: News, Investor updates

Home » Investor Presentation — MagSense® Imaging

Investor Presentation — MagSense^® Imaging

Oct 28, 2019
Posted in: News, Investor updates

Imagion Biosystems announces the presentation “MagSense^® Imaging: Early Detection of Cancer Through Targeted Imaging.”
See the presentation “MagSense^® Imaging“.

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

September 9, 2025

Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer

Dr. Nina Webster Joins IBX Board of Directors

September 1, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging

Executive Chairman Bob Proulx on Pitt Street Research’s Stocks Down Under Podcast: Getting ready for a Phase 2 Study

August 21, 2025

Earlier this month, our own Bob Proulx, Executive Chairman of Imagion Biosystems, had the opportunity to join Stuart Roberts on Pitt Street Research’s podcast Stocks

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Investor Presentation — MagSense^® Imaging

Investor Presentation — MagSense^® Imaging

Related Articles

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Dr. Nina Webster Joins IBX Board of Directors

Executive Chairman Bob Proulx on Pitt Street Research’s Stocks Down Under Podcast: Getting ready for a Phase 2 Study

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list